Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B

DEXCOM INC

2024-FY EPS reported $1.42 revenue$4,033,000,000

Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.
GAAP net income $151.7M ($0.38 diluted EPS) vs $256.3M ($0.62) YoY; non-GAAP EPS $0.45 vs $0.50.
Full year 2024 revenue $4.033B (+11% YoY); GAAP operating margin 14.9% (-160bps); non-GAAP margin 18.8% (-100bps).
Submitted G7 15-day CGM to FDA; secured Dexcom ONE+ reimbursement in France; partnership with ŌURA.
FY2025 guidance: revenue $4.60B (+14% growth); non-GAAP gross margin ~64-65%; operating margin ~21%; Adj. EBITDA ~30%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.